| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Drs. Neuhaus, Strasser-Fuchs, Fazekas, and Archelos), Multiple Sclerosis Research Group, Karl-Franzens-Universität, Graz, Austria; Department of Neurology (Drs. Kieseier and Hartung), Heinrich-Heine-Universität Düsseldorf, Germany; and Department of Neurology (Dr. Niederwieser), Barmherzige Brüder Hospital, Graz, Austria.
Address correspondence and reprint requests to Dr. J.J. Archelos, Department of Neurology, Karl-Franzens-Universität, Auenbruggerplatz 22, 8036 Graz, Austria; e-mail: juan.archelos{at}kfunigraz.ac.at
Background: Recent data suggest that statins may be potent immunomodulatory agents. In order to evaluate the potential role of statins as immunomodulators in MS, the authors studied their immunologic effects in vitro and compared them to interferon (IFN)ß-1b.
Methods: Peripheral blood mononuclear cells (PBMC) obtained from untreated or IFNß-1–treated patients with relapsing-remitting MS or from healthy donors (HD) and T cells were stimulated with concanavalin A, phytohemagglutinin, or antibody to CD3 in the presence of lovastatin, simvastatin, mevastatin, IFNß-1b, or statins plus IFNß-1b. The authors analyzed proliferative activity of T cells and B cells, cytokine production and release, activity of matrix metalloproteinases (MMP), and surface expression of activation markers, adhesion molecules, and chemokine receptors on both T and B cells.
Results: All three statins inhibited proliferation of stimulated PBMC in a dose-dependent manner, with simvastatin being the most potent, followed by lovastatin and mevastatin. IFNß-1b showed a similar effect; statins and IFNß-1b together added their inhibitory potentials. Furthermore, statins reduced the expression of activation-induced adhesion molecules on T cells, modified the T helper 1/T helper 2 cytokine balance, reduced MMP-9, and downregulated chemokine receptors on both B and T cells. Besides strong anti-inflammatory properties, statins also exhibited some proinflammatory effects.
Conclusions: Statins are effective immunomodulators in vitro that merit evaluation as treatment for MS.
This article has been cited by other articles:
|
|
 |
|
  X. Zhang, J. Jin, X. Peng, V. S. Ramgolam, and S. Markovic-Plese Simvastatin Inhibits IL-17 Secretion by Targeting Multiple IL-17-Regulatory Cytokines and by Inhibiting the Expression of IL-17 Transcription Factor RORC in CD4+ Lymphocytes J. Immunol., May 15, 2008; 180(10): 6988 - 6996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Lee, H. Qin, and E. N. Benveniste Simvastatin inhibits IFN-{gamma}-induced CD40 gene expression by suppressing STAT-1{alpha} J. Leukoc. Biol., August 1, 2007; 82(2): 436 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tanaka, C. M. Porter, J. A. Horvath-Arcidiacono, and E. T. Bloom Lipophilic statins suppress cytotoxicity by freshly isolated natural killer cells through modulation of granule exocytosis Int. Immunol., February 1, 2007; 19(2): 163 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Jury, D. A. Isenberg, C. Mauri, and M. R. Ehrenstein Atorvastatin Restores Lck Expression and Lipid Raft-Associated Signaling in T Cells from Patients with Systemic Lupus Erythematosus J. Immunol., November 15, 2006; 177(10): 7416 - 7422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials J. Clin. Oncol., October 20, 2006; 24(30): 4808 - 4817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, T. Koster, C. Morike, S. v. Horsten, U. Martin, M. Bader, A. Haverich, and A. R. Simon Pravastatin prolongs graft survival in an allogeneic rat model of orthotopic single lung transplantation. Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 515 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gold, C. Linington, and H. Lassmann Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research Brain, August 1, 2006; 129(8): 1953 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. R. Coward, A. Marei, A. Yang, M. M. Vasa-Nicotera, and S. C. Chow Statin-Induced Proinflammatory Response in Mitogen-Activated Peripheral Blood Mononuclear Cells through the Activation of Caspase-1 and IL-18 Secretion in Monocytes J. Immunol., May 1, 2006; 176(9): 5284 - 5292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al. Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations Arch Neurol, October 1, 2005; 62(10): 1519 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E C Jury and M R Ehrenstein Statins: immunomodulators for autoimmune rheumatic disease? Lupus, March 1, 2005; 14(3): 192 - 196. [Abstract] [PDF]
|
|
|
|
|
|
M. E. Gegg, R. Harry, D. Hankey, H. Zambarakji, G. Pryce, D. Baker, P. Adamson, V. Calder, and J. Greenwood Suppression of Autoimmune Retinal Disease by Lovastatin Does Not Require Th2 Cytokine Induction J. Immunol., February 15, 2005; 174(4): 2327 - 2335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Samuels Update in Neurology Ann Intern Med, January 4, 2005; 142(1): 28 - 36. [Full Text] [PDF]
|
|
|
|
|
|
B. C. Kieseier, J. J. Archelos, and H.-P. Hartung Different Effects of Simvastatin and Interferon Beta on the Proteolytic Activity of Matrix Metalloproteinases Arch Neurol, June 1, 2004; 61(6): 929 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Law, A. M. Saindane, Y. Ge, J. S. Babb, G. Johnson, L. J. Mannon, J. Herbert, and R. I. Grossman Microvascular Abnormality in Relapsing-Remitting Multiple Sclerosis: Perfusion MR Imaging Findings in Normal-appearing White Matter Radiology, June 1, 2004; 231(3): 645 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. von Tresckow, K.-J. Kallen, E. P. von Strandmann, P. Borchmann, H. Lange, A. Engert, and H. P. Hansen Depletion of Cellular Cholesterol and Lipid Rafts Increases Shedding of CD30 J. Immunol., April 1, 2004; 172(7): 4324 - 4331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Floris, E. L. A. Blezer, G. Schreibelt, E. Dopp, S. M. A. van der Pol, I. L. Schadee-Eestermans, K. Nicolay, C. D. Dijkstra, and H. E. de Vries Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: A quantitative MRI study Brain, March 1, 2004; 127(3): 616 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Silverberg Atorvastatin-Induced Polyneuropathy Ann Intern Med, November 4, 2003; 139(9): 792 - 793. [Full Text] [PDF]
|
|
|
|
 |
|
 O Neuhaus, J J Archelos, and H P Hartung Statins in multiple sclerosis: a new therapeutic option? Multiple Sclerosis, October 1, 2003; 9(5): 429 - 430. [PDF]
|
|
|
|
 |
|
 Statins Have Immunologic Effects in Multiple Sclerosis Journal Watch Neurology, January 10, 2003; 2003(110): 4 - 4. [Full Text]
|
|
|
|
 |
|
 F. Mach Toward a Role for Statins in Immunomodulation Mol. Interv., December 1, 2002; 2(8): 478 - 480. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. S. Zamvil and L. Steinman Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS Neurology, October 8, 2002; 59(7): 970 - 971. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
